Literature DB >> 26565902

p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors.

Xue-Yan He1, Cong Xiang1, Chen-Xi Zhang1, Yin-Yin Xie1, Lai Chen1, Guo-Xin Zhang1, Yi Lu1, Geng Liu2.   

Abstract

Chronic inflammation promotes the development and progression of various epithelial tumors. Wild-type p53 suppresses inflammation, but it is unclear whether the role of p53 in suppression of inflammation is linked to its tumor suppression function. Here, we established mouse models of myeloid lineage-specific p53 deletion or activation to examine its role in inflammation-related intestinal tumorigenesis. Impaired p53 in the myeloid linage resulted in elevated levels of inflammatory mediators and stimulated adenoma initiation in Apc(Min/+) mice. In contrast, mice with mild p53 activation in the myeloid lineage attenuated the inflammatory response and were more resistant to intestinal tumor development and invasion, which were initiated through Apc(Min/+) mutation or carcinogen and promoted by colitis. Furthermore, p53 activation also suppressed alternative (M2) macrophage polarization together with c-MYC downregulation. Therefore, as a regulator of macrophage function, p53 is critical to protection against tumorigenesis in a non-cell-autonomous manner.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26565902     DOI: 10.1016/j.celrep.2015.09.045

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  16 in total

1.  MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.

Authors:  Douglas D Fang; Qiuqiong Tang; Yanhui Kong; Qixin Wang; Jiaxing Gu; Xu Fang; Peng Zou; Tao Rong; Jingwen Wang; Dajun Yang; Yifan Zhai
Journal:  J Immunother Cancer       Date:  2019-11-28       Impact factor: 13.751

Review 2.  Unfolded Protein Response supports endothelial barrier function.

Authors:  Nektarios Barabutis
Journal:  Biochimie       Date:  2019-08-09       Impact factor: 4.079

3.  Ezh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation.

Authors:  Jia Yuan; Qingchen Zhu; Xingli Zhang; Zhenzhen Wen; Guiheng Zhang; Ni Li; Yifei Pei; Yan Wang; Siyu Pei; Jing Xu; Pan Jia; Chao Peng; Wei Lu; Jun Qin; Qian Cao; Yichuan Xiao
Journal:  Cell Death Differ       Date:  2022-05-14       Impact factor: 12.067

Review 4.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 5.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.

Authors:  Maria Esperanza Rodriguez-Ruiz; Ilio Vitale; Kevin J Harrington; Ignacio Melero; Lorenzo Galluzzi
Journal:  Nat Immunol       Date:  2019-12-23       Impact factor: 25.606

6.  Wild-type p53 enhances endothelial barrier function by mediating RAC1 signalling and RhoA inhibition.

Authors:  Nektarios Barabutis; Christiana Dimitropoulou; Betsy Gregory; John D Catravas
Journal:  J Cell Mol Med       Date:  2018-01-24       Impact factor: 5.310

Review 7.  Mitochondrial Retrograde Signalling and Metabolic Alterations in the Tumour Microenvironment.

Authors:  Dongki Yang; Jaehong Kim
Journal:  Cells       Date:  2019-03-22       Impact factor: 6.600

8.  A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.

Authors:  Sang-Soo Kim; Joe B Harford; Manish Moghe; Tiffani Slaughter; Caroline Doherty; Esther H Chang
Journal:  Int J Cancer       Date:  2019-07-08       Impact factor: 7.396

9.  Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.

Authors:  Maya Saison-Ridinger; Kathleen E DelGiorno; Tejia Zhang; Annabelle Kraus; Randall French; Dawn Jaquish; Crystal Tsui; Galina Erikson; Benjamin T Spike; Maxim N Shokhirev; Christopher Liddle; Ruth T Yu; Michael Downes; Ronald M Evans; Alan Saghatelian; Andrew M Lowy; Geoffrey M Wahl
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

10.  AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.

Authors:  Ilyas Sahin; Shengliang Zhang; Arunasalam Navaraj; Lanlan Zhou; Don Dizon; Howard Safran; Wafik S El-Deiry
Journal:  Cell Death Discov       Date:  2020-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.